Pherecydes Pharma SA

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Busy Moderna Inks Gene-Editing Pact Wit

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

Pandion Therapeutics Inc. raised a $58m Series A venture capital round to fund the development of bispecific antibodies for tissue-specific treatment of autoimmune and inflammatory diseases based on